As a part of that effort, we submitted policy proposals to the EC resulting in adoption of key elements in the strategy concerning off-patent competition including the recognition of the need for greater access to generic and biosimilar medicines, the need for new pricing models to address continued viability of access to off-patent medicines, and the importance of repurposing off-patent medicines as a key element of fostering greater competition.